|
 |
|
|||||||
|
|||||||||
© 2003 by the American Diabetes Association, Inc.
Epidemiology/Health Services/Psychosocial Research |
Comparison of Insulin Aspart and Lispro
Pharmacokinetic and metabolic effects
From the General Clinical Research Center and Division of Endocrinology/Diabetes/Metabolism, Temple University School of Medicine, Philadelphia, Pennsylvania
Address correspondence and reprint requests to Guenther Boden, Temple University Hospital, 3401 N. Broad St., Philadelphia, PA 19140. E-mail: bodengh{at}tuhs.temple.edu.
OBJECTIVE—To compare insulin levels and actions in patients with type 1 diabetes after subcutaneous injection of the rapid-acting insulin analogs aspart and lispro.
RESEARCH DESIGN AND METHODS—Seven C-peptide–negative patients with type 1 diabetes (two men and five women) were studied at the General Clinical Research Center at Temple University Hospital two times, 1 month apart. Their plasma glucose was normalized overnight by intravenous infusion of insulin. The next morning, they received subcutaneous injections of either aspart or lispro (9.4 ± 1.9 U) in random order. For the next 4–5 h, their plasma glucose was clamped at 
5.5 mmol/l with a variable infusion of 20% glucose. The study was terminated after 8 h.
RESULTS—Both insulin analogs produced similar serum insulin levels (250–300 pmol/l) at 30 min and disappeared from serum after 4 h. Insulin aspart and lispro had similar effects on glucose and fat metabolism. Effects on carbohydrate metabolism (glucose uptake, glucose oxidation, and endogenous glucose production) peaked after 2–3 h and disappeared after 5–6 h. Effects on lipid metabolism (plasma free fatty acid, ketone body levels, and free fatty acid oxidation) appeared to peak earlier (at 2 h) and disappeared earlier (after 4 h) than the effects on carbohydrate metabolism.
CONCLUSIONS—We conclude that both insulin aspart and lispro are indistinguishable from each other with respect to blood levels and that they are equally effective in correcting abnormalities in carbohydrate and fat metabolism in patients with type 1 diabetes.
Abbreviations: EGP, endogenous glucose production • FFA, free fatty acid • GIR, glucose infusion rate • GRa, rate of glucose appearance • GRd, rate of glucose disappearance
CiteULike 
Del.icio.us 
Digg 
Reddit 
Technorati What's this?
This article has been cited by other articles:
|
|
 |
|
  H. A. Wolpert The Nuts and Bolts of Achieving End Points With Real-Time Continuous Glucose Monitoring Diabetes Care, February 1, 2008; 31(Supplement_2): S146 - S149. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. L. Trujillo Insulin Analogs and Pregnancy Diabetes Spectr, April 1, 2007; 20(2): 94 - 101. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 F. M Regan and D. B Dunger Use of new insulins in children Arch. Dis. Child. Ed. Pract., August 1, 2006; 91(2): ep47 - ep53. [Full Text] [PDF]
|
|
|
|
 |
|
 T. P. Ciaraldi, S. A. Phillips, L. Carter, V. Aroda, S. Mudaliar, and R. R. Henry Effects of the Rapid-Acting Insulin Analog Glulisine on Cultured Human Skeletal Muscle Cells: Comparisons with Insulin and Insulin-Like Growth Factor I J. Clin. Endocrinol. Metab., October 1, 2005; 90(10): 5551 - 5558. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. Plank, A. Siebenhofer, A. Berghold, K. Jeitler, K. Horvath, P. Mrak, and T. R. Pieber Systematic Review and Meta-analysis of Short-Acting Insulin Analogues in Patients With Diabetes Mellitus Arch Intern Med, June 27, 2005; 165(12): 1337 - 1344. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. Alemzadeh, J. N. Ellis, M. K. Holzum, E. A. Parton, and D. T. Wyatt Beneficial Effects of Continuous Subcutaneous Insulin Infusion and Flexible Multiple Daily Insulin Regimen Using Insulin Glargine in Type 1 Diabetes Pediatrics, July 1, 2004; 114(1): e91 - e95. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Diabetes | Diabetes Care | Clinical Diabetes | Diabetes Spectrum |